NCT05811234View on ClinicalTrials.gov

A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults

CompletedOBSERVATIONAL

Enrollment

291

Participants

Timeline

Start Date

June 13, 2023

Primary Completion Date

October 1, 2024

Study Completion Date

October 1, 2024

Conditions

Plaque Psoriasis

Interventions

DRUG

CAL/BDP PAD Cream

As provided in real-world clinical practice.

Trial Locations (37)

Unknown

DE12, Ahaus

DE07, Augsburg

DE06, Cologne

DE08, Freising

DE10, Mainz

DE01, Mannheim

DE05, Mölln

DE03, Mönchengladbach

DE04, Pforzheim

DE02, Potsdam

DE11, Remscheid

ES04, Alcorcón

ES10, Badalona

ES02, Barcelona

ES06, Barcelona

ES09, Barcelona

ES05, Bilbao

ES03, Granollers

ES07, Lleida

ES08, Pontevedra

ES12, Salamanca

ES11, Seville

ES13, Seville

ES01, Zaragoza

UK10, Blackburn

UK02, Chertsey

UK06, Chipping Norton

UK08, Cockermouth

UK03, Crewe

UK07, Exeter

UK14, Glasgow

UK15, Kirkcaldy

UK11, Leicester

UK01, London

UK05, Saint Neots

UK04, Salisbury

UK12, Wellingborough

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Almirall, S.A.

INDUSTRY

NCT05811234 - A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults | Biotech Hunter | Biotech Hunter